FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027266698> ?p ?o ?g. }

• W2027266698 endingPage "B88" @default.
• W2027266698 startingPage "B88" @default.
• W2027266698 abstract "Abstract Background: Deoxyuridine 5'-triphosphate nucleotidehydrolase (dUTPase) is a gatekeeper protein, which prevents uracil misincorporation into DNA in cancer cells. dUTPase may protect cancer cells from aberrant base mediated cytotoxicity during thymidylate synthase (TS) inhibition, and its overexpression is associated with resistance to TS inhibitors. TAS-114 is a novel orally available dUTPase inhibitor and Phase I studies with TS-targeted drugs (S-1 and Capecitabine) are ongoing. Pemetrexed is an antifolate-based TS inhibitor and has been proven efficacious for the treatment of non-squamous non-small cell lung cancer (NSCLC). Here, we evaluated the therapeutic possibility of TAS-114 in combination with pemetrexed in NSCLC models. Materials and Methods: In vitro cell growth inhibition was determined by Crystal Violet, using 14 human lung cancer cell lines. The antitumor activity of TAS-114/pemetrexed was also evaluated in NCI-H2228 (human NSCLC), MX-1 (human breast cancer) and Bu25 TK- (human cervical cancer, thymidine kinase deficient) xenograft mouse models for preclinical proof of concept. MX-1 is a dUTPase highly expressed tumor, and Bu25 TK- is a pemetrexed-sensitve model, due to the lack of thymidine salvage pathway within the tumor cells. Intratumoral dUTPase inhibition was evaluated by measuring the dUTPase enzymatic product dUMP by HPLC. Results: TAS-114 significantly increased the cytotoxicity of pemetrexed in various human NSCLC cell lines in vitro. In an NCI-H2228 xenograft model, pemetrexed alone did not show antitumor activity, but oral administration of TAS-114 significantly enhanced the antitumor activity of pemetrexed. In addition, TAS-114 decreased intratumor dUMP accumulation mediated by pemetrexed-induced TS inhibition. Furthermore, strong antitumor activity of TAS-114/pemetrexed and pharmacodynamic modulation of pemetrexed after administration of TAS-114 were observed in the highly dUTPase expressed tumor MX-1. These results suggested that TAS-114 increased the antitumor activity of pemetrexed by dUTPase inhibition and subsequent uracil misincorporation into DNA. Finally, TAS-114 also enhanced the antitumor activity of pemetrexed in the pemetrexed-sensitive Bu25 TK- xenograft model. Conclusion: TAS-114/pemetrexed combination may represent a novel therapeutic strategy in NSCLC and other solid tumors. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B88. Citation Format: Wakako Yano, Sayaka Tsukioka, Tatsushi Yokogawa, Satoko Ito, Keiji Ishida, Keisuke Yamamura, Akio Fujioka, Masayoshi Fukuoka, Kenichi Matsuo, Kazuharu Noguchi, Teruhiro Utsugi. TAS-114, a dUTPase inhibitor, in combination with pemetrexed is a novel strategy for the treatment of NSCLC. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B88." @default.
• W2027266698 created "2016-06-24" @default.
• W2027266698 creator A5004642359 @default.
• W2027266698 creator A5005597054 @default.
• W2027266698 creator A5006108186 @default.
• W2027266698 creator A5051132319 @default.
• W2027266698 creator A5052200954 @default.
• W2027266698 creator A5059044730 @default.
• W2027266698 creator A5068479821 @default.
• W2027266698 creator A5070666509 @default.
• W2027266698 creator A5076772805 @default.
• W2027266698 creator A5077000893 @default.
• W2027266698 creator A5086224338 @default.
• W2027266698 date "2013-11-01" @default.
• W2027266698 modified "2023-09-27" @default.
• W2027266698 title "Abstract B88: TAS-114, a dUTPase inhibitor, in combination with pemetrexed is a novel strategy for the treatment of NSCLC." @default.
• W2027266698 doi "https://doi.org/10.1158/1535-7163.targ-13-b88" @default.
• W2027266698 hasPublicationYear "2013" @default.
• W2027266698 type Work @default.
• W2027266698 sameAs 2027266698 @default.
• W2027266698 citedByCount "1" @default.
• W2027266698 countsByYear W20272666982020 @default.
• W2027266698 crossrefType "journal-article" @default.
• W2027266698 hasAuthorship W2027266698A5004642359 @default.
• W2027266698 hasAuthorship W2027266698A5005597054 @default.
• W2027266698 hasAuthorship W2027266698A5006108186 @default.
• W2027266698 hasAuthorship W2027266698A5051132319 @default.
• W2027266698 hasAuthorship W2027266698A5052200954 @default.
• W2027266698 hasAuthorship W2027266698A5059044730 @default.
• W2027266698 hasAuthorship W2027266698A5068479821 @default.
• W2027266698 hasAuthorship W2027266698A5070666509 @default.
• W2027266698 hasAuthorship W2027266698A5076772805 @default.
• W2027266698 hasAuthorship W2027266698A5077000893 @default.
• W2027266698 hasAuthorship W2027266698A5086224338 @default.
• W2027266698 hasConcept C121608353 @default.
• W2027266698 hasConcept C123321153 @default.
• W2027266698 hasConcept C126322002 @default.
• W2027266698 hasConcept C185592680 @default.
• W2027266698 hasConcept C2776256026 @default.
• W2027266698 hasConcept C2776694085 @default.
• W2027266698 hasConcept C2777240266 @default.
• W2027266698 hasConcept C2778239845 @default.
• W2027266698 hasConcept C2778397455 @default.
• W2027266698 hasConcept C2780456651 @default.
• W2027266698 hasConcept C2781382166 @default.
• W2027266698 hasConcept C502942594 @default.
• W2027266698 hasConcept C71924100 @default.
• W2027266698 hasConcept C96232424 @default.
• W2027266698 hasConcept C98274493 @default.
• W2027266698 hasConceptScore W2027266698C121608353 @default.
• W2027266698 hasConceptScore W2027266698C123321153 @default.
• W2027266698 hasConceptScore W2027266698C126322002 @default.
• W2027266698 hasConceptScore W2027266698C185592680 @default.
• W2027266698 hasConceptScore W2027266698C2776256026 @default.
• W2027266698 hasConceptScore W2027266698C2776694085 @default.
• W2027266698 hasConceptScore W2027266698C2777240266 @default.
• W2027266698 hasConceptScore W2027266698C2778239845 @default.
• W2027266698 hasConceptScore W2027266698C2778397455 @default.
• W2027266698 hasConceptScore W2027266698C2780456651 @default.
• W2027266698 hasConceptScore W2027266698C2781382166 @default.
• W2027266698 hasConceptScore W2027266698C502942594 @default.
• W2027266698 hasConceptScore W2027266698C71924100 @default.
• W2027266698 hasConceptScore W2027266698C96232424 @default.
• W2027266698 hasConceptScore W2027266698C98274493 @default.
• W2027266698 hasIssue "11_Supplement" @default.
• W2027266698 hasLocation W20272666981 @default.
• W2027266698 hasOpenAccess W2027266698 @default.
• W2027266698 hasPrimaryLocation W20272666981 @default.
• W2027266698 hasRelatedWork W1975243176 @default.
• W2027266698 hasRelatedWork W2029621550 @default.
• W2027266698 hasRelatedWork W2030579631 @default.
• W2027266698 hasRelatedWork W2060774265 @default.
• W2027266698 hasRelatedWork W2095692043 @default.
• W2027266698 hasRelatedWork W2133167126 @default.
• W2027266698 hasRelatedWork W2156983594 @default.
• W2027266698 hasRelatedWork W4233347948 @default.
• W2027266698 hasRelatedWork W4239140667 @default.
• W2027266698 hasRelatedWork W2408712789 @default.
• W2027266698 hasVolume "12" @default.
• W2027266698 isParatext "false" @default.
• W2027266698 isRetracted "false" @default.
• W2027266698 magId "2027266698" @default.
• W2027266698 workType "article" @default.